IRONWOOD PHARMACEUTICALS INC
About IRONWOOD PHARMACEUTICALS INC
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $296.2M
- Net income
- $24.0M
- Total assets
- $396.9M
- Market cap
- $544.9M
- Operating margin
- 33.3%
- Net margin
- 8.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $296.2M
- Operating expenses
- $197.6M
- Operating income
- $98.5M
- Income tax
- $46.0M
- Net income
- $24.0M
- EPS (basic)
- $0.15
- EPS (diluted)
- $0.15
Balance sheet
- Total assets
- $396.9M
- Current assets
- $274.2M
- Total liabilities
- $658.7M
- Current liabilities
- $242.2M
- Shareholders’ equity
- -$261.8M
Cash flow
- Operating cash flow
- $127.0M
- Investing cash flow
- -$34.0K
- Financing cash flow
- $216.0K
- Net cash flow
- $127.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $544.9M
- P/E ratio
- 21.9
- EPS (diluted)
- $0.15
- Shares outstanding
- 165.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 3, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $24.0M in FY2025.
- Revenue declined 28% from FY2021 to FY2025.
- Trading 39% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 21.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review IRONWOOD PHARMACEUTICALS INC.
Write a review
News about IRONWOOD PHARMACEUTICALS INC
News & sentiment via Polygon.io
